ARTICLE | Company News
Amgen, Astellas join list of biopharmas paying for alleged co-pay charity kickbacks
April 26, 2019 7:01 PM UTC
The Department of Justice said Thursday that Amgen and Astellas have agreed to pay $124.8 million combined to settle allegations of kickbacks to charitable patient assistance programs.
Astellas Pharma Inc. (Tokyo:4503) will pay $100 million related to funds for its prostate cancer drug Xtandi enzalutamide, and Amgen Inc. (NASDAQ:AMGN) will pay $24.75 million related to funds for Sensipar cinacalcet and Kyprolis carfilzomib. The DOJ alleged the companies were the sole donor in funds that exclusively covered Medicare patients' co-pays for the biopharmas' drugs. ...